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Abstract
Identification of novel prognostic biomarkers typically requires a large dataset
which provides sufficient statistical power for discovery research. To this end,
we took advantage of the high-throughput data from The Cancer Genome Atlas
(TCGA) to identify a set of prognostic biomarkers in head and neck squamous
cell carcinomas (HNSCC) including oropharyngeal squamous cell carcinoma
(OPSCC) and other subtypes. In this study, we analyzed miRNA-seq data obtained
from TCGA patients to identify prognostic biomarkers for OPSCC. The identified miRNAs were further tested with an independent cohort. miRNA-seq data
from TCGA was also analyzed to identify prognostic miRNAs in oral cavity
squamous cell carcinoma (OSCC) and laryngeal squamous cell carcinoma (LSCC).
Our study identified that miR-193b-3p and miR-455-5p were positively associated with survival, and miR-92a-3p and miR-497-5p were negatively associated
with survival in OPSCC. A combined expression signature of these four miRNAs
was prognostic of overall survival in OPSCC, and more importantly, this signature was validated in an independent OPSCC cohort. Furthermore, we identified four miRNAs each in OSCC and LSCC that were prognostic of survival,
and combined signatures were specific for subtypes of HNSCC. A robust 4-miRNA
prognostic signature in OPSCC, as well as prognostic signatures in other subtypes of HNSCC, was developed using sequencing data from TCGA as the
primary source. This demonstrates the power of using TCGA as a potential
resource to develop prognostic tools for improving individualized patient care.

Introduction
Head and neck squamous cell carcinoma (HNSCC) constitutes approximately 3% of all cancer diagnoses in the United
States, with about 45,000 new cases in 2015 [1]. Among
head and neck cancers, oral cavity, oropharyngeal, and laryngeal cancers are the most common, accounting for 24%,
23%, and 27% of all diagnosed cases, respectively [2].
Due to the heterogeneity of these subtypes of HNSCC,
a single prognostic signature identifying high-and low-
risk patients cannot be generated to cover all types of
HNSCC. However, multiple studies have indicated that

individual biomarkers can stratify high-risk and low-risk
patients within the various subtypes [3–5]. These biomarkers are not limited to coding genes. Included among the
proposed biomarkers are microRNAs (miRNAs), which
are short single-stranded RNA sequences (~22 n.t.) that
function in post-transcriptional regulation. Further studies
have shown that within oropharyngeal cancer, infection
by human papillomavirus (HPV) is a favorable prognostic
marker [6]. Greater prognostic power has been attained
by combining groups of biomarkers into a single signature
for different subtypes of HNSCC, with various degrees
of success [7,8].

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
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The identification of novel biomarkers and subsequent
development of prognostic signatures requires in-
depth
analysis of genetic profiles. For example, high-throughput
gene expression profiling data have been made available
by The Cancer Genome Atlas (TCGA), a joint effort of
the National Cancer Institute and the National Human
Genome Research Institute to provide a comprehensive
set of patient genetic profiles across multiple cancer types
[9]. This has extended to HNSCC, with a total of 529
HNSCC samples being made available [10]. Included in
the available data are RNA-seq and miRNA-seq profiles
for the majority of the provided patient samples.
In this study, we investigated the prognostic value of
miRNA biomarkers for oropharyngeal squamous cell carcinoma (OPSCC), oral squamous cell carcinoma (OSCC),
and laryngeal squamous cell carcinoma (LSCC), using
profiling data obtained from TCGA. These biomarkers
were then used to develop unique prognostic signatures
that robustly predicted overall survival in the respective
subsets of HNSCC. We further demonstrate that use of
the TCGA public dataset can provide a more general
picture of head and neck cancer as the prediction models
obtained can be applied to an independently obtained
dataset. Through a combined analysis of TCGA data and
independently generated data, we have provided an additional set of biomarker tools for the clinical setting that
can assist in determining the best course of treatment
for patients with head and neck cancer.

Materials and Methods
Retrieval of public data
A total of 523 anonymized patients in the TCGA database
were identified as having primary HNSCC. The clinical
patient files were downloaded from TCGA Data Portal
(https://tcga-data.nci.nih.gov/tcga/). Of the 523 HNSCC
patients, 82 patients had a primary tumor in the oropharynx, 313 patients had a primary tumor of the oral
cavity, and 115 patients had primary tumors in the larynx.
A cutoff of 5 years was applied to all patient survival
data.
All gene sequences were downloaded from the UCSC
Genome Browser [11]. Index files mapping transcript
accessions to NCBI Gene IDs were downloaded from the
NCBI ftp site [12]. All mature miRNA sequences were
downloaded from miRBase [13]. Raw miRNA-
seq data
was obtained for 81 of the 82 OPSCC patients, 311 of
313 OSCC patients, and all of the laryngeal cancer patients.
Raw RNA-
seq data was obtained for 72 of the 82
oropharyngeal cancer patients. All raw RNA-

seq and
miRNA-
seq files were downloaded through the Cancer
Genomics Hub [14].
1620
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TCGA sequence analysis
Sequence alignment was performed using the Bowtie program [15]. Raw miRNA-
seq reads were aligned to the
human miRNome. The read counts were then normalized
to reads per million reads mapped per sample and set
to a floor value of 1 for lowly expressed miRNAs. Raw
RNA-seq reads were aligned sequentially to human RefSeq
annotated sequences, the human reference genome, and
the virome. The read counts were normalized to reads
per kilobase per million mapped reads, and then to the
2000th gene before being set to a floor of five normalized
reads for lowly expressed mRNAs. Both miRNA-seq and
RNA-seq reads were subsequently log2 normalized.

Statistical analysis for survival and
correlation
Overall survival analysis was conducted using the “survival”
package in R (http://www.r-project.org). Correlation and
covariance analysis was conducted in MATLAB [16].
Univariate Cox proportional hazards regression analyses
were performed to evaluate the correlation between individual miRNAs or mRNAs with overall survival. The
P-
values for outcome correlation were calculated using
the Wald test. The final prognostic signatures were also
evaluated in this manner. Multivariate Cox proportional
hazards analyses were conducted to evaluate the independent prognostic value of the miRNA signature after controlling for common clinical variables. The Kaplan–Meier
estimator was used to determine the empirical survival
probabilities and P-values from the log-rank test indicated
the significance of the miRNA prediction outcome model.

Collection of independent validation data
sets
A total of 95 OPSCC cases were included in this study
for validation. Patients were treated at Washington
University School of Medicine with definitive chemoradiation, or with primary surgery followed by radiation therapy
with or without chemotherapy. Clinical data were collected
from the patients and then updated retrospectively after
follow-up review.
For all 95 of the patients, formalin-
fixed, paraffin-
embedded (FFPE) tumor tissues were collected for
pathological analysis before radiotherapy or chemotherapy. Sections from each case were stained with
hematoxylin and eosin, and reviewed by a study pathologist at the Washington University to confirm the diagnoses. Tumor regions from each section were identified
and macrodissection was conducted. Total RNA was
extracted from the identified tumor regions using the

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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miRNeasy FFPE kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. In total, 66 patients
were used for the validation of the OPSCC miRNA
prognostic model and 39 patients were used for the
validation of the OPSCC mRNA model.

Quantitative reverse-transcription PCR for
miRNA model validation
Quantitative reverse-transcription polymerase chain reaction
(qRT-PCR) was used to profile the miRNAs identified as
significant in OPSCC. The details of this experimental procedure have been described previously [17]. Briefly, the RT
reaction was performed with the High Capacity cDNA
Reverse Transcription Kit (Life Technologies, Foster City,
CA, USA). Each RT reaction included 100 ng of tumor
RNA and a pool of RT primers for selected miRNAs and
control RNAs. Quantitative PCR was performed with Power
SYBR Green PCR Master Mix (Life Technologies) and specific PCR primers for selected miRNAs or control RNAs.
miRNA raw profiling data for individual samples were
normalized with four small RNA controls (SNORD48,
SNORD47, RNA5-8S5, and RNU6-1). Specifically, the expression levels of the four small RNAs were averaged and used
as the reference to control for sample variations during
miRNA profiling analysis.
The expression of p16 protein was determined by
immunohistochemistry as previously described [18]. The
expression profiles of E6 and E7 transcripts from six
oncogenic HPV types were determined by qRT-
PCR,
including types 16, 18, 33, 39, 56, and 59. The details
of the HPV assays and the experimental protocol have
been described previously [18]. In brief, primer sequences
for the assays were selected from the E6 and E7 coding
regions of the high-
risk HPV genomes. The expression
profiles of GAPDH and β-
actin were used as reference
controls for data normalization.

Results
Validation of an existing miRNA prognostic
signature
To verify whether the miRNA data obtained from The
Cancer Genome Atlas (TCGA) could be used in further
biomarker identification, we evaluated our previously published prognostic model for OPSCC [8] with TCGA data.
Briefly, this model identified miR-24-3p, miR-31-5p, and
miR-
193b-
3p as negatively associated with survival, and
miR-26b-5p, miR-142-3p, and miR-146a-5p as positively
associated with survival. The expression levels of these
six miRNAs were then combined to create a single prognostic model as described previously [8]:

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

A

miRNA Name Fold change
miR-24-3p
miR-31-5p
miR-193b-3p
miR-26b-5p
miR-142-3p
miR-146a-5p

0.08
0.14
0.83
-0.33
-0.31
-0.30

P-value
0.62
0.11
4.6E-03
0.097
0.065
0.05

B

Figure 1. Validation of an existing miRNA signature with TCGA data.
(A) The six miRNAs from our previously published prognostic model for
OPSCC were examined for association with the overall survival of TCGA
patients. Fold change values were log2 transformed and represent the
average expression difference of the miRNAs in the deceased patient
group compared to the living patient group. Statistical significance was
determined with the log-rank test in Cox regression analysis. (B) Kaplan–
Meier survival analysis to evaluate the prognostic performance of the
six-miRNA signature for predicting overall survival in OPSCC.

S = 2.62EmiR-24-3p + 3.16EmiR-31-5p + 2.45EmiR-193b-3p
− 2.69EmiR-26b-5p − 3.34EmiR-142-3p − 2.81EmiR-146a-5p
We examined each miRNA individually with TCGA data
and found that two miRNAs were significantly associated with
survival, two miRNAs maintained borderline significance
(P < 0.1), and two miRNAs was not found to be significant
(P > 0.1) (Fig. 1A). It should be noted, however, that the
directions of expression changes in relation to survival outcome
were maintained for all six miRNAs (i.e., positive correlations
for miR-26b-5p, miR-142-3p, miR-146a-5p, and negative correlations for miR-31-5p, miR-193b-3p, miR-26b-5p) (Fig. 1A).
When we analyzed this prognostic model as whole, it was able
to significantly differentiate between high-and low-risk OPSCC
patients from TCGA (Fig. 1B). This demonstrated that this
previously published model was robust and could be applied
to patient miRNA profiles obtained from other institutions,
while also indicating that the data from TCGA was a valuable
resource for further biomarker identification and analysis.
1621
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Unique TCGA miRNA expression profiles
correlated with overall survival in OPSCC
miRNA expression analysis was performed for the 81
OPSCC patients obtained from TCGA. The characteristics
of these patients are summarized in Table 1. The miRNAs
were examined individually using Cox univariate proportional hazards analysis to determine which miRNAs were
correlated with overall survival. This analysis provides a
log-rank P-value, which indicates the significance of the
miRNA in relation to survival, as well as a Wald coefficient, which indicates the weight associated with the
expression level of the miRNA.
We then implemented recursive feature elimination
(RFE) technique to determine the relative prognostic performance of individual miRNAs. In this process, a regression model was generated using the given miRNA features
and outcomes (i.e., miRNA expression and overall survival,
respectively), and the least impactful feature was

N. Wong et al.

eliminated. The process was then repeated until the final
iteration identified the most significant feature associated
with the classifier. This was performed on a subset of
top-ranking 189 miRNAs in OPSCC ordered by log-rank
P-value while maintaining a Wald coefficient greater than
or equal to one, and an average expression across all
samples greater than 1.414 (i.e., a log2 Expression of 0.5).
In this way, we were able to initially identify a set of
promising miRNA candidates for further model
development.
In examining the 50 most significant miRNAs in accordance with the RFE, miR-193b-3p, miR-455-5p, miR-92a-3p,
and miR-
497-
5p were identified as maintaining a high
RFE ranking after 10-fold cross-validation, as well as being
statistically significant in the univariate Cox proportional
hazards analysis (Fig. 2). All four of these miRNAs have
been reported as dysregulated in other cancer types, including colorectal cancer and pancreatic cancer [19–22]. In

Table 1. Characteristics of the HNSCC patients included in TCGA.
Characteristics

OPSCC (n = 81)

OSCC (n = 311)

LSCC (n = 115)

Age at diagnosis (mean ± SD,
years)
Sex
Male
Female
Race
White
Other
Smoking1
Unreported
Nonsmoker
Long-term former smoker
Other former smoker
Current smoker
T classification
T1
T2
T3
T4
N Classification
NX
N0
N1
N2
N3
Stage
I
II
III
IV
Deceased

55.9 ± 9.3

61.9 ± 13.2

61.9 ± 9.1

69 (85.2%)
12 (14.8%)

206 (66.2%)
105 (33.8%)

95 (82.6%)
20 (17.4%)

75 (92.6%)
6 (7.4%)

268 (86.2%)
43 (13.8%)

91 (79.1%)
24 (20.9%)

1 (1.2%)
25 (30.8%)
8 (9.9%)
25 (30.9%)
22 (27.2%)

10 (3.2%)
88 (28.3%)
51 (16.4%)
68 (21.9%)
94 (30.2%)

4 (3.5%)
6 (5.2%)
11 (9.6%)
36 (31.3%)
58 (50.4%)

13 (16.0%)
36 (44.4%)
20 (24.7%)
12 (14.8%)

29 (9.3%)
102 (32.8%)
64 (20.6%)
116 (37.3%)

7 (6.1%)
20 (17.4%)
33 (28.7%)
55 (47.8%)

0 (0.0%)
21 (25.9%)
52 (64.2%)
3 (3.7%)
5 (6.2%)

4 (1.3%)
142 (45.7%)
52 (16.7%)
110 (35.4%)
3 (1.0%)

2 (1.7%)
52 (45.2%)
12 (10.4%)
46 (40.0%)
3 (2.6%)

5 (6.2%)
11 (13.6%)
12 (14.8%)
53 (65.4%)
14 (17.2%)

19 (6.1%)
62 (19.9%)
57 (18.3%)
173 (55.6%)
109 (35.0%)

2 (1.7%)
15 (13.0%)
18 (15.7%)
80 (69.6%)
33 (28.7%)

OPSCC, oropharyngeal squamous cell carcinoma; OSCC, oral cavity squamous cell carcinoma; LSCC, laryngeal squamous cell carcinoma; SD, standard
deviation.
1Smoking was defined as no history of smoking, a former smoker of ≥15 years, other former smoker of <15 years, or a current smoker.
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Figure 2. Four significant miRNAs associated with overall survival of TCGA OPSCC patients. Fold change values were log2 transformed and represent
the average expression difference of the miRNAs in the deceased patient group compared to the living patient group. Significance was determined
with the log-rank test in Cox regression analysis.

particular, the validity of miR-
193b-
3p as a prognostic
marker in OPSCC was previously reported and incorporated in our previous model for outcome prediction [8].

A combined miRNA prognostic signature
predicts overall survival in OPSCC
We further hypothesized that a combination of prognostic
miRNAs within OPSCC could be effectively used to predict
overall survival. The miRNAs chosen in the aforementioned
analysis were used to build the following prognostic model:

SOPSCC = 11.31EmiR-193b-3p + 13.53EmiR-455-5p
− 7.25EmiR-92a-3p − 7.3EmiR-497-5p ,
where S indicates the risk score for each patient and E
represents the normalized expression level of the identified
miRNA from the primary tumor. The coefficients in this
equation are the Wald scores from the Cox regression
analysis and are representative of the relative importance
of the miRNA toward survival status.
In this prediction model, higher scores indicate higher
risk and predict a poor survival outcome for the patient.

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

The patients were stratified internally by median risk score
to produce two cohorts of similar size, so as to determine
the validity of the prognostic model. By this method, 40
OPSCC patients were predicted to be high-
risk (with >
median score) and 41 patients were predicted to be low-risk
(i.e., with ≤ median score); significantly different risks of
death were observed based on this classification (P = 6.8E-
04) (Fig. 3A).
One primary concern for prognostic model development
is the risk of overtraining. To address this issue, we performed leave-
one-
out cross-
validation. For this cross-
validation, within each iteration, we removed one sample
from the training set and trained a model with the miRNA
profiles from the remaining samples. The removed sample
was then used for independent model testing. The process
was repeated until all the samples had been used independently for model testing. For each validation round, the
Wald coefficient for the candidate miRNAs were calculated
based on the training set and used to generate a slightly
different model for testing. Cross-validation still yielded a
significant separation of high-and low-risk patients (Fig. 3B),
indicating that the model is robust within the training data.
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A

B

C

D

Figure 3. Kaplan–Meier survival analysis to evaluate the novel OPSCC 4-miRNA prognostic signature. Patients were stratified into the low-risk group
or high-risk group based on risk score. (A) The signature was evaluated for overall survival in the training set from TCGA. Significance was determined
using the log-rank test. (B) Leave-one-out cross-validation to evaluate the miRNA modeling strategy. The cross-validated results from all rounds were
combined for prognostic evaluation of overall survival. (C) Independence of the miRNA signature in HPV(+) patients. (D) Survival analysis to evaluate
the miRNA signature for overall survival in the validation cohort.

The miRNA prognostic signature was
independent of clinical features
We assessed whether the miRNA signature maintained
its prognostic value within the context of commonly used
clinical parameters, including age at diagnosis, gender,
race, smoking history, initial tumor staging, and treatment type. This analysis was conducted through multivariate Cox hazards analysis. This miRNA signature was
found to maintain statistical significance, with a hazards
ratio of 11.85 and P-value of 3.9E-03 (Table S1).

The OPSCC miRNA signature maintained its
prognostic value independent of HPV
status
Previous work has shown that HPV positivity is a favorable
prognostic marker in OPSCC, and thus we extended our
miRNA signature to explore whether the prognostic
1624

significance was maintained independent of HPV status.
OPSCC patients were identified as HPV-positive if sequencing reads from the RNA-seq data that did not align to
the human genome aligned to any of the 143 types of
HPV. Of the 72 OPSCC patients with RNA-seq data, 46
were identified as having reads aligned to one of three
types of HPV. Specifically, 39 patients were positive for
HPV16, four for HPV33, and three for HPV35, leaving
26 patients as HPV-negative.
Of the 46 patients who were identified as HPV-positive,
35 were identified as low-risk and 11 as high-risk by the
miRNA prognostic signature. Kaplan–Meier survival analysis indicated that the high-risk group had poor survival
as compared to the low-risk group (P = 7.9E-03) (Fig. 3C).
The model was not statistically significant when applied
to HPV-negative patients (data not shown); however, it
should be noted that the HPV-negative set was a much
smaller cohort (n = 26), which significantly reduced the
power of the model.

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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A

B

C

D

Figure 4. Kaplan–Meier survival analysis to evaluate the OSCC and LSCC miRNA prognostic models. (A, B) The models were evaluated in the
respective training sets. (C, D) Leave-one-out cross-validation results were combined for prognostic evaluation.

Validation of the OPSCC miRNA signature
with an independent cohort
To confirm the validity of the 4-miRNA model for OPSCC
prognosis, we applied our miRNA signature to an independent cohort of 66 OPSCC patients treated at the
Washington University School of Medicine in St. Louis.
The clinical characteristics of these patients are outlined
in Table S2. We hypothesized that the miRNA signature
provides independent prognostic value from HPV biomarker. Since HPV positivity is a favorable prognostic
marker for OPSCC, we were interested to know whether
the new miRNA signature maintains its prognostic value
by further risk-stratifying HPV-positive patients.
All 66 patients were preselected to be p16-positive by
immunohistochemistry, as p16 is a robust surrogate biomarker for HPV expression [18]. HPV expression in these
tumors was further validated by quantitative reverse-
transcription PCR (qRT-PCR, see Materials and Methods
for details). Of the 66 tumors, 61 were HPV16-positive
and two were HPV18-positive. HPV transcripts were not
detected in the remaining three samples.

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Furthermore, qRT-PCR was conducted on the tumor
samples for the four miRNAs included in the signature.
miRNA expression readings were normalized using four
internal small RNA controls (see Materials and Methods
for details). The risk score was then calculated for each
of these patients based on the miRNA signature. The
patients were then stratified into high-risk and low-risk
groups by the median risk score. Kaplan–Meier survival
analysis indicated that the miRNA model was significantly
predictive of survival outcome for the 63 HPV-
positive
cases (P = 1.6E-03, Fig. 3D). The miRNA signature had
a similar prognostic performance when applied to all 66
p16-positive cases (P = 2.8E-03).
We also analyzed the signature prediction scores with
a receiver operating characteristic curve, which evaluated
both the true positive rate (sensitivity) and the false positive rate (specificity). In the training and validation sets,
the areas under the curve were 0.84 and 0.84, respectively,
indicating robust performance of the model for both
sensitivity and specificity when applied to independent
cohorts (Figure S1).
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Unique miRNA expression profiles
correlated with distinct subtypes of head
and neck cancer
We extended our miRNA expression profiling analysis to
the 311 OSCC and 115 LSCC patients obtained from
TCGA. The characteristics of these patients are summarized
in Table 1. For each additional subtype of HNSCC, we
conducted similar analyses as described for OPSCC and
identified four miRNAs in each subset that were predictive
of overall survival (Table S5). These miRNAs were then
combined to generate the following prognostic models:

SOSCC = 10.73EmiR-337-3p + 7.82EmiR-369-5p
+ 6.21EmiR-218-5p + 7.01EmiR-127-5p ,
SLSCC = −10.70Elet-7a-3p − 6.96EmiR-145-5p
+ 4.59EmiR-129-5p − 6.43EmiR-26b-5p
As described earlier, the median score was used within
each subset to separate patients into high-and low-
risk
groups, which were also found to have significantly different risks of death (P = 1.8E-04 in OSCC and P = 2.4E-
03 for LSCC) (Fig. 4A and B). We also conducted
leave-one-out cross-validation analysis for these two signatures and found a significantly different risk of survival
in the miRNA-stratified groups of OSCC and a borderline
significance for LSCC (Fig. 4C and D). Despite borderline
significance of the LSCC model in cross-validation analysis,
the LSCC prognostic miRNA model may still be useful
for prediction of patient survival. In particular, these models
maintained statistical significance independent of clinical
features when analyzed with multivariate Cox analysis, with
the OSCC model having a hazards ratio of 1.88 and a
P-value of 1.8E-03, and the LSCC model having a hazards
ratio of 2.84 and a P-value of 1.3E-02 (Table S1).
It is noteworthy that each miRNA signature carried
prognostic significance when applied to the HNSCC subtype where it was derived. On the other hand, when
applied to other subtypes of HNSCC, none of the signatures were able to effectively distinguish high-risk and
low-risk patients (Figure S2). We also observed this phenomenon when we applied the previously developed
6-miRNA prognostic model to OSCC and LSCC (Figure
S3). In conjunction with previous studies indicating significant genetic heterogeneity between subtypes of HNSCC
[10], our results indicate that the miRNome is just as
unique for each HNSCC subtype.

Discussion
Identification of novel prognostic biomarkers typically
requires a large dataset, which provides sufficient statistical
1626
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power for discovery research. To this end, we took advantage of the high-throughput data from TCGA for biomarker
analysis. The TCGA consortium has published many studies
identifying the mutations and dysregulations associated
with tumors in comparison to matched normal tissue
samples. There are also a number of studies that used
TCGA data for independent validation of existing biomarkers [23–25]. Additionally, many studies exploring
miRNA biomarkers in head and neck cancer, such as the
miR-34 family and miR-200a, have indicated their roles
in oncogenesis [26]. However, few studies have utilized
TCGA data in systematically identifying biomarkers associated with patient outcome.
In this study, we have presented a new strategy to
identify prognostic miRNA biomarkers by analyzing TCGA
data directly, followed by experimental validation using
an independent cohort. As the first step, we utilized TCGA
data as the primary source to identify biomarkers and
develop prognostic models for OPSCC. Within OPSCC,
infection by HPV has already been indicated as a favorable
prognostic factor [6]. Our model was able to further
improve the prognostic value of HPV positivity by identifying a high-risk cohort among HPV(+) patients. Next,
we were able to validate the robustness of this signature
using an independent cohort that consisted only of HPV(+)
OPSCC patients. This confirmed that the miRNA signature
was able to further distinguish high-and low-risk patients
within HPV(+) OPSCC patients.
Among the subtypes of HNSCC, OPSCC has unique
characteristics as HPV infection is associated with most
OPSCC cases. Although the total number of HNSCC cases
has decreased steadily on a yearly basis, the number of
reported OPSCC cases has increased significantly as a
result of rapid rise in HPV(+) OPSCC cases [27,28]. Our
clinical goal of building a powerful prognostic model is
to reliably stratify OPSCC patients for treatment failures
after standard therapy. The availability of such a reliable
prognostic model is critical for providing individualized
cancer therapy, including both deintensifying treatment
for low-risk patients as well as intensification for high-risk
patients. In particular, there is currently significant clinical
interest in identifying a subset of OPSCC patients who
have low-risk of treatment failures, in order to deintensify
their overall treatment. As present, multi-institutional de-
escalation clinical trials are underway for HPV(+) OPSCC
patients [29,30]. However, there is still a significant portion of HPV(+) OPSCC cases that have poor outcome.
For these cases, de-
escalation treatment should not be
applied and instead the treatment should be intensified.
Thus, there is a critical need to develop robust prognostic
models to further stratify HPV(+) OPSCC patients for
enrollment in de-escalation trials. To this end, our proposed miRNA-based prognostic model will fill in a critical

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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need by selecting HPV(+) OPSCC patients who will most
likely benefit from de-escalation treatment. Further work
would be required to bring this signature fully to the
clinical setting, such as the inclusion of robust reference
genes to standardize the signature scores, which allows
clinicians to determine the appropriate treatment modality
based a predefined threshold score.
Besides OPSCC, we have also shown that our strategy
on TCGA-based biomarker discovery can be extended to
the study of other subtypes of HNSCC. In this way, we
have demonstrated that TCGA represents a rich resource
for cancer prognostic studies. We expect that prognostic
tools developed using TCGA data, with proper validation,
will significantly expand our ability to more precisely
manage cancer patients by applying individualized treatment plans.
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